In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...
NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment. Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23...
Novo Nordisk and Aspect Biosystems expand collaboration to accelerate curative diabetes therapies The landscape of regenerative medicine has shifted significantly following the announcement that Novo Nordisk and Aspect Biosystems are entering a comprehensive new phase...
GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...
We all know or work with people who can be difficult to deal with and even talk to, and we all know or work with other people who are a joy to be around and who make the working day a little brighter. Some of those difficult people will be highly competent in their...
Metformin has been the first line drug treatment for type 2 diabetes for more than two decades and remains one of the most widely prescribed medicines globally. Its effectiveness, low cost and long safety record have made it a cornerstone of diabetes care. However, as...
Metformin has been the first line drug treatment for type 2 diabetes for more than two decades and remains one of the most widely prescribed medicines globally. Its effectiveness, low cost and long safety record have made it a cornerstone of diabetes care. However, as...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...
Concerns are mounting that the United Kingdom’s official appraisal framework is systematically underestimating the economic and social value of investments in life sciences manufacturing. Industry bodies and independent analysts warn that the methods used to evaluate...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
Manufacturing and supply chain resilience has moved to the forefront of strategic planning across the life sciences industry as advanced therapies place unprecedented strain on existing production models. Cell therapies, gene therapies, mRNA platforms and increasingly...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
By early Q4 2025, global pharma M&A had already crossed $70B in announced value, driven heavily by a handful of mega-deals, more than 2024, and tracking toward the highest levels since the post-2015 boom. Unlike 2023–24, this wave isn’t driven by small tuck-ins....
As the pharmaceutical industry undergoes rapid transformation, a new paradigm is taking shape. Known as Pharma 5.0, it represents more than an upgrade in technology, it is a fundamental shift toward human-centric innovation, sustainable manufacturing, and intelligent...
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a novel, next-generation chimeric antigen receptor T-cell (CAR-T) therapy for use in the National Health Service (NHS). This landmark decision is set to...
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...